Bopindolol

DB08807ExperimentalSmall molecule

Bopindolol (INN) is an ester prodrug for the beta blocker pindolol.

Mechanism: Bopindolol (as pindolol) non-selectively blocks beta-1 adrenergic receptors mainly in the heart, inhibiting the effects of epinephrine and norepinephrine resulting in a decrease in heart rate and blood pressure. By binding beta-2 receptors in the juxtaglomerular apparatus, Pindolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production and therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.
Curator reviewed
Primary indication: For the management of hypertension, edema, ventricular tachycardias, and atrial fibrillation.Curator reviewed
Formula / weight: C₂₃H₂₈N₂O₃ · 380.48 g/mol (avg)

Resolves to

Compound

UNIIKT304VZO57CAS62658-63-3ChEMBLCHEMBL357995ChEBI143782PubChem44112KEGGD07537

Clinical / RWD

RxNorm19605ATCC07AA17ATCC07CA17PharmGKBPA165958425

Structure

InChIKeyUUOJIACWOAYWEZ-UHFFFAOYSA-NSMILESCC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1

Targets

P08588ADRB1P07550ADRB2P13945ADRB3P08908HTR1AP28222HTR1B

What you can answer from here — as of August 26, 2024

5Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1,085Drug interactionsStructured to mechanism, not free text

2ATC codesIncluding every combination product, plus 15 drug categories

28+ReferencesStructured and connected to the statements they support

Which drugs share a target with Bopindolol, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In